-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $201

Benzinga·08/06/2026 15:47:02
Listen to the news
Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $192.1 to $201.